Disc Medicine (NASDAQ: IRON) COO exercises options, sells 18,612 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Disc Medicine, Inc. Chief Operating Officer Yu Jonathan Yen-Wen reported option exercises and related share sales. On June 16, 2026, he exercised stock options for a total of 18,612 shares of common stock at an exercise price of $9.86 per share and sold 18,612 shares in open-market transactions. The sales occurred at weighted average prices of about $68.76 and $69.92 per share, within ranges from $68.37 to $70.19. The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 18,612 shares ($1,287,801)
Net Sell
6 txns
Insider
Yu Jonathan Yen-Wen
Role
Chief Operating Officer
Sold
18,612 shs ($1.29M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 5,261 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 13,351 | $0.00 | -- |
| Exercise | Common Stock | 5,261 | $9.86 | $52K |
| Exercise | Common Stock | 13,351 | $9.86 | $132K |
| Sale | Common Stock | 11,651 | $68.7582 | $801K |
| Sale | Common Stock | 6,961 | $69.918 | $487K |
Holdings After Transaction:
Stock Option (Right to Buy) — 1,753 shares (Direct, null);
Common Stock — 59,585 shares (Direct, null)
Footnotes (1)
- These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.37 to $69.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.40 to $70.19, inclusive. The shares underlying this option are fully vested and exercisable as of the date hereof.
Key Figures
Shares sold (total): 18,612 shares
Sale tranche 1: 11,651 shares at $68.7582
Sale tranche 2: 6,961 shares at $69.918
+3 more
6 metrics
Shares sold (total)
18,612 shares
Common Stock open-market sales on June 16, 2026
Sale tranche 1
11,651 shares at $68.7582
Weighted average price; trades from $68.37 to $69.36
Sale tranche 2
6,961 shares at $69.918
Weighted average price; trades from $69.40 to $70.19
Options exercised (total)
18,612 shares
Derivative exercises converting options into common stock
Option exercise price
$9.86 per share
Conversion or exercise price for Stock Option (Right to Buy)
10b5-1 plan adoption date
March 17, 2026
Rule 10b5-1 trading plan governing June 16, 2026 trades
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security
4 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What insider transaction did Disc Medicine (IRON) report for its COO?
Disc Medicine reported that COO Yu Jonathan Yen-Wen exercised stock options and sold common shares. On June 16, 2026, he exercised options for 18,612 shares at $9.86 and sold 18,612 shares in open-market trades at weighted average prices in the high-$60 range.
Did the Disc Medicine (IRON) COO exercise stock options in this Form 4 filing?
Yes. The filing shows the COO exercised stock options covering 13,351 shares and 5,261 shares of Disc Medicine common stock. Both option tranches had a conversion or exercise price of $9.86 per share, turning option awards into directly held common shares.
What does the weighted average price disclosure mean in this Disc Medicine Form 4?
The Form 4 notes that the reported prices are weighted averages for multiple trades. Shares were sold in numerous individual transactions within specified price ranges, and the insider offers to provide exact share counts at each price to the issuer, shareholders, or SEC staff upon request.
What type of derivative securities did the Disc Medicine (IRON) COO exercise?
He exercised “Stock Option (Right to Buy)” derivatives linked to Disc Medicine common stock. Two option lines covered 13,351 and 5,261 underlying shares, each with a $9.86 exercise price, and the filing notes the underlying shares were fully vested and exercisable as of the transaction date.